Evidence map›Paper›PMID 28115275›Full record

ReviewBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation.

Andrew C Dietz, Parinda A Mehta, Adrianna Vlachos, Sharon A Savage, Dorine Bresters, Jakub Tolar, Farid Boulad, Jean Hugues Dalle, Carmem Bonfim, Josu de la Fuente and 6 more

Open access · bronzeAbstract readConsensus StatementReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Late Effects Following Hematopoietic Stem Cell Transplantation Among Childhood Transplant Survivors with Fanconi AnemiaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Germline mutations: many roles in leukemogenesis.Current opinion in hematology · 2020
    Review
  15. Monitoring and treatment of MDS in genetically susceptible persons.Hematology. American Society of Hematology. Education Program · 2019
    Article
  16. Article
  17. How I manage children with Diamond-Blackfan anaemia.British journal of haematology · 2019
    Review
  18. Review
  19. Inherited bone marrow failure syndromes: considerations pre- and posttransplant.Hematology. American Society of Hematology. Education Program · 2017
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 5 countries.

Andrew C DietzChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California. Electronic address: adietz@chla.usc.edu.
Parinda A MehtaDivision of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Adrianna VlachosHofstra Northwell School of Medicine, Feinstein Institute for Medical Research, Cohen Children's Medical Center, Division of Hematology/Oncology and Stem Cell Transplantation, New Hyde Park, New York.
Sharon A SavageClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Dorine BrestersWillem-Alexander Children's Hospital, SCT Unit, Leiden University Medical Center, Leiden, The Netherlands.
Jakub TolarBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Farid BouladBone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Division of Pediatric Hematology/Oncology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York.
Jean Hugues DalleUniversité Paris 7, Hôpital Robert-Debré, Service d'hémato-immunologie, Paris, France.
Carmem BonfimHospital de Clinicas, Federal University of Parana, Curitiba, Brazil.
Josu de la FuenteSection of Paediatrics, Imperial College, London, United Kingdom; Department of Paediatric Haematology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.
Christine N DuncanDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Michael A PulsipherChildren's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California.
Jeffrey M LiptonHofstra Northwell School of Medicine, Feinstein Institute for Medical Research, Cohen Children's Medical Center, Division of Hematology/Oncology and Stem Cell Transplantation, New Hyde Park, New York.
John E WagnerBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota.
Blanche P AlterClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Feinstein Institute for Medical Research · USNational Cancer Institute · USUniversity of Minnesota · USUniversity of Southern California · USCincinnati Children's Hospital Medical Center · USDana-Farber/Boston Children's Cancer and Blood Disorders Center · USFred Hutch Cancer Center · USHospital de Clínicas Universidade Federal do Paraná · BRImperial College Healthcare NHS Trust · GBLeiden University Medical Center · NLMemorial Sloan Kettering Cancer Center · USUniversité Paris Cité · FR

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8M
Pediatric Blood and Marrow Transplant ConsortiumU01HL069254 · NHLBI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI PULSIPHER, MICHAEL A · 2001 to 2010
$2.0M
BONE MARROW TRANSPLANT (BMT) SURVIVORS STUDYR01CA078938 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BHATIA, SMITA · 2000 to 2003
$1.6M
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant ConsortiumUG1HL069254 · NHLBI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S · 2017 to 2023
$1.3M
Blood and Marrow Transplant Clinical Trials NetworkU10HL069254 · NHLBI · UNIVERSITY OF UTAH · PI PULSIPHER, MICHAEL A · 2011 to 2016
$839k
Late Effects after Pediatric HSCT: State of the Science, Future DirectionsR13CA159788 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI BAKER, KEVIN S, PULSIPHER, MICHAEL A · 2011 to 2011
$13k
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA078938NCI NIH HHS R13 CA159788NHLBI NIH HHS U01 HL069254NHLBI NIH HHS U10 HL069254NHLBI NIH HHS UG1 HL069254
6 · The paper itself

Abstract

Fanconi anemia (FA), dyskeratosis congenita (DC), and Diamond Blackfan anemia (DBA) are 3 of the most common inherited bone marrow failure syndromes (IBMFS), in which the hematologic manifestations can be cured with hematopoietic cell transplantation (HCT). Later in life, these patients face a variety of medical conditions, which may be a manifestation of underlying disease or due to pre-HCT therapy, the HCT, or a combination of all these elements. Very limited long-term follow-up data exist in these populations, with FA the only IBMFS that has specific published data. During the international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium entitled "Late Effects Screening and Recommendations following Allogeneic Hematopoietic Cell Transplant (HCT) for Immune Deficiency and Nonmalignant Hematologic Disease" held in Minneapolis, Minnesota in May of 2016, a half-day session was focused specifically on the unmet needs for these patients with IBMFS. A multidisciplinary group of experts discussed what is currently known, outlined an agenda for future research, and laid out long-term follow-up guidelines based on a combination of evidence in the literature as well as expert opinion. This article addresses the state of science in that area as well as consensus regarding the agenda for future research, with specific screening guidelines to follow in the next article from this group.

Indexed as

Long Term Adverse EffectsAnemia, AplasticAnemia, Diamond-BlackfanBiomedical ResearchBone Marrow DiseasesBone Marrow Failure DisordersChildDyskeratosis CongenitaFanconi AnemiaForecastingHematopoietic Stem Cell TransplantationHemoglobinuria, ParoxysmalHumansDiamond Blackfan anemiaDyskeratosis congenitaFanconi anemiaInherited bone marrow failure syndromesLate effectsPediatric allogeneic hematopoietic cell transplantation

Identifiers

PMID28115275
PMCPMC5423755
OpenAlexW2577516487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.